[PERSON]
psoriasis
Featured in 2 tracked stories · first seen
Situations
Novo Nordisk pivots strategy to counter patent cliff
112 clusters · 548 sources · last updated
Latest: Novo Nordisk faces intense competition in obesity drug market
Novo Nordisk is implementing a strategic reset to address long-term growth concerns and the looming patent expiration of semaglutide in the early 2030s. To diversify its portfolio and counter competition from Eli Lilly,
Also covered in
-
Psoriasis symptoms and skin changes
[HEALTH] · 3 sources ·